Korea United Pharm Inc. (033270.KS)
KRW 18480.0
(-1.75%)
KRW 18480.0
(-1.75%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 54.94 Billion KRW | 14.64% |
| 2022 | 48.21 Billion KRW | 45.11% |
| 2021 | 33.22 Billion KRW | -17.2% |
| 2020 | 40.12 Billion KRW | 16.38% |
| 2019 | 34.47 Billion KRW | -8.67% |
| 2018 | 37.75 Billion KRW | 19.02% |
| 2017 | 31.71 Billion KRW | 16.96% |
| 2016 | 27.11 Billion KRW | 18.34% |
| 2015 | 22.91 Billion KRW | 4.22% |
| 2014 | 21.98 Billion KRW | 48.19% |
| 2013 | 14.83 Billion KRW | -25.1% |
| 2012 | 19.81 Billion KRW | -15.98% |
| 2011 | 23.57 Billion KRW | 8.38% |
| 2010 | 21.75 Billion KRW | 13.2% |
| 2009 | 19.21 Billion KRW | 57.13% |
| 2008 | 12.23 Billion KRW | 74.2% |
| 2007 | 7.02 Billion KRW | -1.21% |
| 2006 | 7.1 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 15.05 Billion KRW | 20.15% |
| 2024 Q1 | 16.86 Billion KRW | 57.21% |
| 2024 Q2 | 12.53 Billion KRW | -25.71% |
| 2023 Q4 | 10.72 Billion KRW | -33.01% |
| 2023 Q3 | 16.01 Billion KRW | -0.15% |
| 2023 Q2 | 16.03 Billion KRW | 28.38% |
| 2023 Q1 | 12.49 Billion KRW | 638.09% |
| 2023 FY | 55.27 Billion KRW | 14.64% |
| 2022 FY | 48.21 Billion KRW | 45.11% |
| 2022 Q3 | 27.95 Billion KRW | 37.08% |
| 2022 Q1 | 11.11 Billion KRW | 43.04% |
| 2022 Q2 | 20.38 Billion KRW | 83.52% |
| 2022 Q4 | -2.32 Billion KRW | -108.31% |
| 2021 Q3 | 8.6 Billion KRW | -6.56% |
| 2021 Q4 | 7.76 Billion KRW | -9.69% |
| 2021 Q1 | 7.65 Billion KRW | -28.13% |
| 2021 FY | 33.22 Billion KRW | -17.2% |
| 2021 Q2 | 9.2 Billion KRW | 20.27% |
| 2020 Q1 | 9.27 Billion KRW | -14.51% |
| 2020 Q2 | 9.42 Billion KRW | 1.55% |
| 2020 Q3 | 10.77 Billion KRW | 14.35% |
| 2020 Q4 | 10.64 Billion KRW | -1.18% |
| 2020 FY | 40.12 Billion KRW | 16.38% |
| 2019 Q1 | 8.33 Billion KRW | -27.3% |
| 2019 Q3 | 8.21 Billion KRW | 16.19% |
| 2019 FY | 34.47 Billion KRW | -8.67% |
| 2019 Q4 | 10.85 Billion KRW | 32.07% |
| 2019 Q2 | 7.07 Billion KRW | -15.13% |
| 2018 FY | 37.75 Billion KRW | 19.02% |
| 2018 Q4 | 11.46 Billion KRW | 33.42% |
| 2018 Q1 | 9.45 Billion KRW | 49.6% |
| 2018 Q2 | 8.24 Billion KRW | -12.86% |
| 2018 Q3 | 8.59 Billion KRW | 4.26% |
| 2017 Q1 | 6.6 Billion KRW | -12.07% |
| 2017 Q3 | 11.7 Billion KRW | 65.05% |
| 2017 Q2 | 7.08 Billion KRW | 7.35% |
| 2017 FY | 31.71 Billion KRW | 16.96% |
| 2017 Q4 | 6.32 Billion KRW | -45.98% |
| 2016 Q2 | 5.59 Billion KRW | -26.05% |
| 2016 Q4 | 7.51 Billion KRW | 16.73% |
| 2016 Q3 | 6.43 Billion KRW | 14.91% |
| 2016 FY | 27.11 Billion KRW | 18.34% |
| 2016 Q1 | 7.57 Billion KRW | 0.0% |
| 2015 FY | 22.91 Billion KRW | 4.22% |
| 2015 Q4 | - KRW | -100.0% |
| 2015 Q3 | 3.96 Billion KRW | -34.24% |
| 2015 Q2 | 6.02 Billion KRW | -5.51% |
| 2015 Q1 | 6.37 Billion KRW | -3.51% |
| 2014 Q4 | 6.61 Billion KRW | 20.81% |
| 2014 FY | 21.98 Billion KRW | 48.19% |
| 2014 Q1 | 4.7 Billion KRW | 60.07% |
| 2014 Q3 | 5.47 Billion KRW | 5.34% |
| 2014 Q2 | 5.19 Billion KRW | 10.41% |
| 2013 Q4 | 2.93 Billion KRW | 0.72% |
| 2013 FY | 14.83 Billion KRW | -25.1% |
| 2013 Q1 | 5.27 Billion KRW | 28.83% |
| 2013 Q2 | 3.7 Billion KRW | -29.76% |
| 2013 Q3 | 2.91 Billion KRW | -21.2% |
| 2012 Q3 | 4.2 Billion KRW | -24.36% |
| 2012 Q4 | 4.09 Billion KRW | -2.55% |
| 2012 FY | 19.81 Billion KRW | -15.98% |
| 2012 Q1 | 7.51 Billion KRW | 0.0% |
| 2012 Q2 | 5.55 Billion KRW | -26.11% |
| 2011 Q3 | 7.36 Billion KRW | -2.71% |
| 2011 Q2 | 7.56 Billion KRW | 8.72% |
| 2011 FY | 23.57 Billion KRW | 8.38% |
| 2011 Q1 | 6.95 Billion KRW | 38.07% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q2 | 5.75 Billion KRW | 36.27% |
| 2010 Q1 | 4.22 Billion KRW | -6.4% |
| 2010 Q4 | 5.04 Billion KRW | -25.15% |
| 2010 Q3 | 6.73 Billion KRW | 16.99% |
| 2010 FY | 21.75 Billion KRW | 13.2% |
| 2009 Q4 | 4.51 Billion KRW | 8.73% |
| 2009 FY | 19.21 Billion KRW | 57.13% |
| 2009 Q1 | 4.94 Billion KRW | 27.28% |
| 2009 Q2 | 5.6 Billion KRW | 13.24% |
| 2009 Q3 | 4.15 Billion KRW | -25.94% |
| 2008 Q4 | 3.88 Billion KRW | 106.38% |
| 2008 Q2 | 2.85 Billion KRW | -15.95% |
| 2008 Q1 | 3.39 Billion KRW | 0.0% |
| 2008 FY | 12.23 Billion KRW | 74.2% |
| 2008 Q3 | 1.88 Billion KRW | -34.05% |
| 2007 Q2 | 2.63 Billion KRW | 0.0% |
| 2007 Q3 | 1.85 Billion KRW | -29.73% |
| 2007 FY | 7.02 Billion KRW | -1.21% |
| 2006 FY | 7.1 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -14973.827% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 28.527% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 169.065% |
| HANDOK Inc. | 12.57 Billion KRW | -336.843% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 2862.481% |
| Yuhan Corporation | 74.56 Billion KRW | 26.304% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -391.568% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 404.557% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 75.565% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -1698.057% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -282.913% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -9113.52% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -5601.564% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -103.281% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -14973.827% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 808.475% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -1262.289% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 178.555% |
| JW Holdings Corporation | 143.66 Billion KRW | 61.752% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 202.868% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 77.717% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 45.217% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 215.946% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -693.276% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -749.165% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -529.336% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -14973.827% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | -12.677% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 58.81% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 45.217% |
| Yuhan Corporation | 74.56 Billion KRW | 26.304% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -162.663% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -1662.68% |
| Suheung Co., Ltd. | 42.99 Billion KRW | -27.805% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 45.217% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -168.252% |
| CKD Bio Corp. | -20.15 Billion KRW | 372.669% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -70.478% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -117.175% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | -68.945% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 215.946% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | -65.776% |
| Boryung Corporation | 68.26 Billion KRW | 19.508% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 246.545% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -282.913% |
| JW Lifescience Corporation | 32.09 Billion KRW | -71.228% |